
Cris Loiren Rodriguez
Supervisory Patent Examiner (ID: 13791, Phone: (571)272-4964 , Office: P/3732 )
| Most Active Art Unit | 3763 |
| Art Unit(s) | 3306, 3772, 1612, 3734, 3633, 2763, 3763, 3732, 3783 |
| Total Applications | 1175 |
| Issued Applications | 574 |
| Pending Applications | 326 |
| Abandoned Applications | 279 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17844923
[patent_doc_number] => 11434276
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-09-06
[patent_title] => Polypeptides with altered binding to neonatal Fc receptor (FcRn) and methods of use
[patent_app_type] => utility
[patent_app_number] => 17/317782
[patent_app_country] => US
[patent_app_date] => 2021-05-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 63
[patent_figures_cnt] => 120
[patent_no_of_words] => 31940
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 93
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17317782
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/317782 | Polypeptides with altered binding to neonatal Fc receptor (FcRn) and methods of use | May 10, 2021 | Issued |
Array
(
[id] => 17035149
[patent_doc_number] => 20210252107
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-19
[patent_title] => NOVEL THERAPY
[patent_app_type] => utility
[patent_app_number] => 17/313463
[patent_app_country] => US
[patent_app_date] => 2021-05-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9368
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17313463
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/313463 | NOVEL THERAPY | May 5, 2021 | Pending |
Array
(
[id] => 17214543
[patent_doc_number] => 20210347880
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-11
[patent_title] => Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
[patent_app_type] => utility
[patent_app_number] => 17/308302
[patent_app_country] => US
[patent_app_date] => 2021-05-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45636
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 114
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17308302
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/308302 | Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody | May 4, 2021 | Pending |
Array
(
[id] => 18369126
[patent_doc_number] => 11649280
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-05-16
[patent_title] => Antibodies to IL-34
[patent_app_type] => utility
[patent_app_number] => 17/238549
[patent_app_country] => US
[patent_app_date] => 2021-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 13320
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17238549
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/238549 | Antibodies to IL-34 | Apr 22, 2021 | Issued |
Array
(
[id] => 19242023
[patent_doc_number] => 12012442
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-06-18
[patent_title] => Activatable fusion protein and use thereof
[patent_app_type] => utility
[patent_app_number] => 17/234005
[patent_app_country] => US
[patent_app_date] => 2021-04-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 6453
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 104
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17234005
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/234005 | Activatable fusion protein and use thereof | Apr 18, 2021 | Issued |
Array
(
[id] => 19897877
[patent_doc_number] => 12275783
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-04-15
[patent_title] => Antibodies that bind interleukin-10 receptor-2 peptides, compositions, and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 17/221218
[patent_app_country] => US
[patent_app_date] => 2021-04-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 5343
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17221218
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/221218 | Antibodies that bind interleukin-10 receptor-2 peptides, compositions, and methods of use thereof | Apr 1, 2021 | Issued |
Array
(
[id] => 17307383
[patent_doc_number] => 11208476
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-12-28
[patent_title] => Polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP
[patent_app_type] => utility
[patent_app_number] => 17/208046
[patent_app_country] => US
[patent_app_date] => 2021-03-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 14
[patent_no_of_words] => 40536
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17208046
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/208046 | Polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP | Mar 21, 2021 | Issued |
Array
(
[id] => 17111808
[patent_doc_number] => 20210292405
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-23
[patent_title] => METHODS FOR TREATING HEPCIDIN-MEDIATED DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/195757
[patent_app_country] => US
[patent_app_date] => 2021-03-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26912
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17195757
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/195757 | METHODS FOR TREATING HEPCIDIN-MEDIATED DISORDERS | Mar 8, 2021 | Abandoned |
Array
(
[id] => 17052205
[patent_doc_number] => 20210261639
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-26
[patent_title] => COMPOSITIONS COMPRISING AN INTERLEUKIN CONSTRUCT
[patent_app_type] => utility
[patent_app_number] => 17/192183
[patent_app_country] => US
[patent_app_date] => 2021-03-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17166
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -30
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17192183
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/192183 | COMPOSITIONS COMPRISING AN INTERLEUKIN CONSTRUCT | Mar 3, 2021 | Abandoned |
Array
(
[id] => 16930929
[patent_doc_number] => 20210196818
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-01
[patent_title] => VACCINES WITH INTERLEUKIN-33 AS AN ADJUVANT
[patent_app_type] => utility
[patent_app_number] => 17/188648
[patent_app_country] => US
[patent_app_date] => 2021-03-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29540
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -31
[patent_words_short_claim] => 8
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17188648
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/188648 | VACCINES WITH INTERLEUKIN-33 AS AN ADJUVANT | Feb 28, 2021 | Pending |
Array
(
[id] => 17036732
[patent_doc_number] => 20210253690
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-19
[patent_title] => Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 Antibody
[patent_app_type] => utility
[patent_app_number] => 17/175129
[patent_app_country] => US
[patent_app_date] => 2021-02-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57742
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 248
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17175129
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/175129 | Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 Antibody | Feb 11, 2021 | Abandoned |
Array
(
[id] => 16868577
[patent_doc_number] => 20210162044
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-03
[patent_title] => METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS
[patent_app_type] => utility
[patent_app_number] => 17/165724
[patent_app_country] => US
[patent_app_date] => 2021-02-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29916
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 86
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17165724
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/165724 | METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS | Feb 1, 2021 | Abandoned |
Array
(
[id] => 16899050
[patent_doc_number] => 20210177966
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-17
[patent_title] => METHODS OF TREATING ANKYLOSING SPONDYLITIS USING IL-17 ANTAGONISTS
[patent_app_type] => utility
[patent_app_number] => 17/165729
[patent_app_country] => US
[patent_app_date] => 2021-02-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39229
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17165729
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/165729 | METHODS OF TREATING ANKYLOSING SPONDYLITIS USING IL-17 ANTAGONISTS | Feb 1, 2021 | Abandoned |
Array
(
[id] => 19763191
[patent_doc_number] => 12221464
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-02-11
[patent_title] => Methods of treatment of IL-17A associated conditions
[patent_app_type] => utility
[patent_app_number] => 17/163961
[patent_app_country] => US
[patent_app_date] => 2021-02-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 61
[patent_figures_cnt] => 61
[patent_no_of_words] => 40435
[patent_no_of_claims] => 32
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 239
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17163961
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/163961 | Methods of treatment of IL-17A associated conditions | Jan 31, 2021 | Issued |
Array
(
[id] => 16900787
[patent_doc_number] => 20210179703
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-17
[patent_title] => Method of Treating Psoriasis with Anti-IL23 Specific Antibody
[patent_app_type] => utility
[patent_app_number] => 17/164384
[patent_app_country] => US
[patent_app_date] => 2021-02-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31185
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 166
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17164384
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/164384 | Method of Treating Psoriasis with Anti-IL23 Specific Antibody | Jan 31, 2021 | Abandoned |
Array
(
[id] => 17198684
[patent_doc_number] => 20210338778
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-04
[patent_title] => METHODS FOR TREATMENT OF MICROBIAL DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/162924
[patent_app_country] => US
[patent_app_date] => 2021-01-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41347
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17162924
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/162924 | METHODS FOR TREATMENT OF MICROBIAL DISORDERS | Jan 28, 2021 | Abandoned |
Array
(
[id] => 17020954
[patent_doc_number] => 20210244825
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-12
[patent_title] => IL-21 ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 17/155773
[patent_app_country] => US
[patent_app_date] => 2021-01-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26949
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 354
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17155773
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/155773 | IL-21 ANTIBODIES | Jan 21, 2021 | Abandoned |
Array
(
[id] => 16776611
[patent_doc_number] => 20210113688
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-22
[patent_title] => METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS
[patent_app_type] => utility
[patent_app_number] => 17/127738
[patent_app_country] => US
[patent_app_date] => 2020-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29930
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 103
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17127738
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/127738 | METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS | Dec 17, 2020 | Abandoned |
Array
(
[id] => 16806173
[patent_doc_number] => 20210128726
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-06
[patent_title] => METHODS OF TREATING ANKYLOSING SPONDYLITIS USING IL-17 ANTAGONISTS
[patent_app_type] => utility
[patent_app_number] => 17/127758
[patent_app_country] => US
[patent_app_date] => 2020-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39221
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 90
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17127758
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/127758 | METHODS OF TREATING ANKYLOSING SPONDYLITIS USING IL-17 ANTAGONISTS | Dec 17, 2020 | Abandoned |
Array
(
[id] => 17141722
[patent_doc_number] => 20210309734
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-07
[patent_title] => ANTIBODY MOLECULES WHICH BIND IL-17A AND IL-17F
[patent_app_type] => utility
[patent_app_number] => 17/122752
[patent_app_country] => US
[patent_app_date] => 2020-12-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10670
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17122752
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/122752 | Expression vector encoding antibody molecule which binds IL-17A and IL-17F | Dec 14, 2020 | Issued |